share_log

Inozyme Pharma Analyst Ratings

Inozyme Pharma Analyst Ratings

Inozyme 製藥分析師評級
Benzinga ·  2023/11/08 04:51
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/08/2023 656.58% Needham → $23 Reiterates Buy → Buy
09/27/2023 656.58% Needham → $23 Reiterates Buy → Buy
09/08/2023 393.42% Wedbush → $15 Maintains Outperform
08/09/2023 656.58% Needham → $23 Reiterates Buy → Buy
08/08/2023 426.32% HC Wainwright & Co. → $16 Reiterates Buy → Buy
08/04/2023 426.32% HC Wainwright & Co. $19 → $16 Maintains Buy
07/27/2023 656.58% Needham → $23 Reiterates Buy → Buy
05/10/2023 656.58% Needham → $23 Reiterates → Buy
04/19/2023 656.58% Needham → $23 Reiterates → Buy
03/23/2023 97.37% Jefferies $4.5 → $6 Upgrades Hold → Buy
03/23/2023 656.58% Needham → $23 Reiterates → Buy
02/17/2023 557.89% HC Wainwright & Co. → $20 Reiterates → Buy
02/17/2023 656.58% Needham → $23 Reiterates → Buy
05/26/2022 64.47% Jefferies → $5 Initiates Coverage On → Hold
05/11/2022 557.89% HC Wainwright & Co. $33 → $20 Maintains Buy
03/16/2022 722.37% Wedbush $35 → $25 Maintains Outperform
02/07/2022 985.53% HC Wainwright & Co. → $33 Initiates Coverage On → Buy
11/29/2021 656.58% Needham → $23 Initiates Coverage On → Buy
08/18/2020 1051.32% Wedbush → $35 Initiates Coverage On → Outperform
08/18/2020 985.53% B of A Securities → $33 Initiates Coverage On → Buy
08/18/2020 — Cowen & Co. Initiates Coverage On → Outperform
08/18/2020 1215.79% Piper Sandler → $40 Initiates Coverage On → Overweight
日期 上行/下行 分析師事務所 目標價格變動 評級變動 之前/當前的評級
11/08/2023 656.58% 尼德姆 → 23 美元 重申 購買 → 購買
09/27/2023 656.58% 尼德姆 → 23 美元 重申 購買 → 購買
09/08/2023 393.42% Wedbush → 15 美元 維護 跑贏大盤
08/09/2023 656.58% 尼德姆 → 23 美元 重申 購買 → 購買
08/08/2023 426.32% HC Wainwright & Co. → 16 美元 重申 購買 → 購買
08/04/2023 426.32% HC Wainwright & Co. 19 美元 → 16 美元 維護 購買
07/27/2023 656.58% 尼德姆 → 23 美元 重申 購買 → 購買
05/10/2023 656.58% 尼德姆 → 23 美元 重申 → 購買
04/19/2023 656.58% 尼德姆 → 23 美元 重申 → 購買
03/23/2023 97.37% 傑富瑞集團 4.5 美元 → 6 美元 升級 持有 → 買入
03/23/2023 656.58% 尼德姆 → 23 美元 重申 → 購買
02/17/2023 557.89% HC Wainwright & Co. → 20 美元 重申 → 購買
02/17/2023 656.58% 尼德姆 → 23 美元 重申 → 購買
2022 年 5 月 26 日 64.47% 傑富瑞集團 → 5 美元 啓動覆蓋範圍開啓 → 按住
05/11/2022 557.89% HC Wainwright & Co. 33 美元 → 20 美元 維護 購買
2022 年 3 月 16 日 722.37% Wedbush 35 美元 → 25 美元 維護 跑贏大盤
2022 年 7 月 2 日 985.53% HC Wainwright & Co. → 33 美元 啓動覆蓋範圍開啓 → 購買
11/29/2021 656.58% 尼德姆 → 23 美元 啓動覆蓋範圍開啓 → 購買
08/18/2020 1051.32% Wedbush → 35 美元 啓動覆蓋範圍開啓 → 跑贏大盤
08/18/2020 985.53% B of A 類證券 → 33 美元 啓動覆蓋範圍開啓 → 購買
08/18/2020 — Cowen & Co. 啓動覆蓋範圍開啓 → 跑贏大盤
08/18/2020 1215.79% 派珀·桑德勒 → 40 美元 啓動覆蓋範圍開啓 → 超重

What is the target price for Inozyme Pharma (INZY)?

Inozyme Pharma（INZY）的目標價格是多少？

The latest price target for Inozyme Pharma (NASDAQ: INZY) was reported by Needham on November 8, 2023. The analyst firm set a price target for $23.00 expecting INZY to rise to within 12 months (a possible 656.58% upside). 13 analyst firms have reported ratings in the last year.

Needham於2023年11月8日公佈了Inozyme Pharma（納斯達克股票代碼：INZY）的最新目標股價。該分析公司將目標股價設定爲23.00美元，預計INZY將在12個月內上漲至23.00美元（可能上漲656.58％）。去年有13家分析公司公佈了評級。

What is the most recent analyst rating for Inozyme Pharma (INZY)?

Inozyme Pharma（INZY）的最新分析師評級是多少？

The latest analyst rating for Inozyme Pharma (NASDAQ: INZY) was provided by Needham, and Inozyme Pharma reiterated their buy rating.

Inozyme Pharma（納斯達克股票代碼：INZY）的最新分析師評級由尼德姆提供，Inozyme Pharma重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for Inozyme Pharma (INZY)?

Inozyme Pharma（INZY）的下一個分析師評級何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Inozyme Pharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Inozyme Pharma的最後一次評級是在2023年11月8日提交的，因此您應該預計下一個評級將在2024年11月8日左右公佈。

Is the Analyst Rating Inozyme Pharma (INZY) correct?

分析師對Inozyme Pharma（INZY）的評級是否正確？

While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a reiterated with a price target of $0.00 to $23.00. The current price Inozyme Pharma (INZY) is trading at is $3.04, which is within the analyst's predicted range.

儘管評級是主觀的，並將發生變化，但Inozyme Pharma（INZY）的最新評級得到了重申，目標股價爲0.00美元至23.00美元。Inozyme Pharma（INZY）目前的交易價格爲3.04美元，在分析師的預測區間內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論